The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

F. Saad

Consultant or Advisory Role - Millennium

Research Funding - Millennium

H. Akaza

Consultant or Advisory Role - Millennium

Honoraria - Takeda

M. A. Eisenberger

Honoraria - Millennium

J. Nelson

Consultant or Advisory Role - Millennium

H. I. Scher

Consultant or Advisory Role - Aragon Pharmaceuticals (U); Bristol-Myers Squibb (U); Centocor Ortho Biotech (U); Enzon; Medivation (U); Millennium; Veridex (U)

Stock Ownership - Johnson & Johnson

K. Suzuki

Consultant or Advisory Role - Millennium

Honoraria - Takeda

Research Funding - Takeda

M. Wirth

Consultant or Advisory Role - Takeda

I. J. Webb

Employment or Leadership Position - Millennium

J. Wang

Employment or Leadership Position - Millennium

D. MacLean

Employment or Leadership Position - Millennium

R. De Wit

Consultant or Advisory Role - Millennium

Honoraria - Millennium